scholarly article | Q13442814 |
P356 | DOI | 10.3816/CLC.2010.N.101 |
P953 | full work available at URL | https://api.elsevier.com/content/article/PII:S1525730411700444?httpAccept=text/plain |
https://api.elsevier.com/content/article/PII:S1525730411700444?httpAccept=text/xml | ||
P698 | PubMed publication ID | 21071331 |
P2093 | author name string | Frank Beier | |
Charles Butts | |||
Glenwood Goss | |||
Denis Soulières | |||
Andrew Maksymiuk | |||
Kevin Jasas | |||
Peter M. Ellis | |||
Guy Ely | |||
R. Nevin Murray | |||
Colum J. Smith | |||
P2860 | cites work | Consolidation Docetaxel After Concurrent Chemoradiotherapy in Stage IIIB Non–Small-Cell Lung Cancer: Phase II Southwest Oncology Group Study S9504 | Q44438556 |
Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology | Q46253129 | ||
Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 S | Q46641106 | ||
Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. | Q46672565 | ||
Heterogeneity of mucin gene expression in normal and neoplastic tissues | Q53482902 | ||
The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in ?pure? ductal carcinoma in situ of the breast | Q57892833 | ||
Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy | Q71254387 | ||
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer | Q73181790 | ||
Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer | Q79345729 | ||
Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003 | Q80345591 | ||
The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma | Q80654652 | ||
Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer | Q81231679 | ||
Cancer statistics, 2009 | Q29547625 | ||
Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). | Q33299169 | ||
Estimates of the cancer incidence and mortality in Europe in 2006. | Q34575047 | ||
Mucins: structure, function, and associations with malignancy | Q35284163 | ||
Contribution of membrane mucins to tumor progression through modulation of cellular growth signaling pathways | Q36752265 | ||
L-BLP25: a peptide vaccine strategy in non small cell lung cancer | Q36899928 | ||
Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide | Q37186715 | ||
Strategies used for MUC1 immunotherapy: preclinical studies | Q37259594 | ||
Immunotherapy for lung cancer | Q37435397 | ||
Oligosaccharide differences in the DF3 sialomucin antigen from normal human milk and the BT-20 human breast carcinoma cell line | Q38345618 | ||
P433 | issue | 6 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | lung cancer | Q47912 |
P304 | page(s) | 391-395 | |
P577 | publication date | 2010-11-01 | |
P1433 | published in | Clinical Lung Cancer | Q332299 |
P1476 | title | A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer | |
A Multicenter Open-Label Study to Assess the Safety of a New Formulation of BLP25 Liposome Vaccine in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer | |||
P478 | volume | 11 |
Q40342047 | Active-specific immunotherapy for non-small cell lung cancer |
Q34494018 | Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response |
Q36088986 | Canertinib induces ototoxicity in three preclinical models |
Q58804834 | Combining immunotherapy with radiation therapy in thoracic oncology |
Q34269196 | EGFR-mediated carcinoma cell metastasis mediated by integrin αvβ5 depends on activation of c-Src and cleavage of MUC1. |
Q34044082 | INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer |
Q90053061 | Immunomodulatory Nanosystems |
Q38022807 | Immunotherapies for non-small-cell lung cancer and mesothelioma. |
Q52624364 | Immunotherapy in surgically resectable non-small cell lung cancer. |
Q37698684 | Influence of human immune cells on cancer: studies at the University of Colorado |
Q34430511 | L-BLP25 as a peptide vaccine therapy in non-small cell lung cancer: a review |
Q34418761 | Liposomes as vaccine delivery systems: a review of the recent advances |
Q38091088 | MUC1-specific cytotoxic T lymphocytes in cancer therapy: induction and challenge |
Q35886589 | Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study |
Q58740200 | New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1 |
Q26997993 | Particle-mediated delivery of cytokines for immunotherapy |
Q44991597 | Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial |
Q35886761 | Tecemotide: an antigen-specific cancer immunotherapy |
Q46720677 | Translational nanoparticle engineering for cancer vaccines. |
Q84534783 | Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial |
Q36207901 | Why has active immunotherapy not worked in lung cancer? |
Q54380709 | [Progress in Immunotherapy for Squamous Non-small Cell Lung Cancer]. |
Search more.